In a report released today, Marc Frahm from TD Cowen maintained a Buy rating on Inozyme Pharma (INZY – Research Report). The company’s shares opened today at $1.14. Effectively assess a stock ...
H.C. Wainwright lowered the firm’s price target on UroGen Pharma (URGN) to $55 from $64 and keeps a Buy rating on the shares. The company reported a “modest” revenue miss, but its long-term ...
News Medical on MSN4d
LGM Pharma invests $6 M in U.S. drug manufacturing capabilities for liquids, suspensions, semi-solids, and suppositoriesLGM Pharma, a leading provider of tailored API and CDMO services for the full drug product lifecycle, today announced an investment of over $6 million to expand its Rosenberg, Texas manufacturing ...
Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly The U.S. Food and Drug Administration's chief ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback